Repligen (RGEN) director receives new RSU and stock option grants
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Repligen Corporation director Nicolas Barthelemy reported compensation-related equity grants. He was awarded 995 restricted stock units, each representing one share of Common Stock, and 2,239 stock options with an exercise price of $103.38 per share.
The RSUs and option award vest in full on the earlier of May 14, 2027, one year from the grant date, or the date of the next annual shareholder meeting. Barthelemy has elected to defer settlement of the RSUs under Repligen’s Deferred Compensation Plan for Non-Employee Directors, with shares to be delivered after his service as a director ends. Following these grants, he directly holds 5,436 shares of Common Stock and 2,239 options.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
BARTHELEMY NICOLAS
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 2,239 | $0.00 | -- |
| Grant/Award | Common Stock | 995 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 2,239 shares (Direct, null);
Common Stock — 5,436 shares (Direct, null)
Footnotes (1)
- Mr. Barthelemy was awarded 995 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 14, 2027, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The Reporting Person has elected to defer settlement of these restricted stock units pursuant to the Repligen Corporation Deferred Compensation Plan for Non-Employee Directors. Once vested, the shares will be issued in accordance with the Reporting Person's deferral election following the separation of the Reporting Person's service as a Director. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Award vests in full on the earlier of May 14, 2027, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined.
Key Figures
RSU grant: 995 units
Option grant size: 2,239 options
Option exercise price: $103.38 per share
+4 more
7 metrics
RSU grant
995 units
Restricted stock units awarded to director on May 14, 2026
Option grant size
2,239 options
Stock Option (Right to Buy) awarded on May 14, 2026
Option exercise price
$103.38 per share
Conversion/exercise price for 2,239 stock options
Common shares held after grant
5,436 shares
Total Common Stock directly owned following RSU grant
Options held after grant
2,239 options
Total Stock Option (Right to Buy) position following grant
Option vesting date trigger
May 14, 2027
Options vest on earlier of this date or next annual meeting
Option expiration
May 14, 2036
Expiration date of Stock Option (Right to Buy)
Key Terms
restricted stock units, Deferred Compensation Plan for Non-Employee Directors, Stock Option (Right to Buy), Grant, award, or other acquisition, +1 more
5 terms
restricted stock units financial
"Mr. Barthelemy was awarded 995 restricted stock units."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Deferred Compensation Plan for Non-Employee Directors financial
"defer settlement of these restricted stock units pursuant to the Repligen Corporation Deferred Compensation Plan for Non-Employee Directors."
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
Grant, award, or other acquisition financial
"transaction_code_description: "Grant, award, or other acquisition""
vest in full financial
"Award vests in full on the earlier of May 14, 2027..."
FAQ
What did Repligen (RGEN) director Nicolas Barthelemy receive in this Form 4 filing?
Nicolas Barthelemy received equity compensation awards. He was granted 995 restricted stock units and 2,239 stock options for Repligen Common Stock, reflecting routine director compensation rather than an open-market stock purchase or sale.
How large are Nicolas Barthelemy’s new stock option awards in Repligen (RGEN)?
Barthelemy received 2,239 stock options. These options give him the right to buy 2,239 Repligen Common Stock shares at an exercise price of $103.38 per share, vesting on the earlier of May 14, 2027 or the next annual shareholder meeting.
When do Nicolas Barthelemy’s restricted stock units in Repligen (RGEN) vest?
The 995 restricted stock units vest in a single tranche. They vest on the earlier of May 14, 2027, one year from the grant date, or the date of Repligen’s next annual shareholders’ meeting, which the company notes has not yet been determined.
How are Nicolas Barthelemy’s RSUs in Repligen (RGEN) settled after vesting?
The RSUs are settled in Repligen Common Stock after service ends. Barthelemy elected to defer settlement under the Deferred Compensation Plan for Non-Employee Directors, so vested shares will be issued following his separation from service as a director.
What does the Form 4 show about Nicolas Barthelemy’s Repligen (RGEN) holdings after these grants?
After the grants, Barthelemy holds additional equity exposure. He directly owns 5,436 shares of Repligen Common Stock and 2,239 stock options linked to Common Stock, all reported as direct ownership in the Form 4 filing.